All Hong Kong stocks quotes are at least 15 minutes delayed.
00241
ALI HEALTH
HKD
7.170-0.610
(-7.84%)
1D
High
7.710
Open
7.710
VWAP
7.23
Vol
549.49M
Mkt Cap
88.80B
Low
6.950
Amount
3.98B
EV/EBITDA(TTM)
60.37
Total Shares
16.17B
EV
14.82B
EV/OCF(TTM)
64.75
P/S(TTM)
3.48
Alibaba Health Information Technology Ltd is an investment holding company mainly engaged in the provision of Internet solutions for the medical and pharmaceutical industry, and is Alibaba Group’s healthcare flagship platform. The Company is mainly involved in the development of pharmaceutical and healthcare product and service sales business, the operation of pharmaceutical e-commerce platform and consumer healthcare services platform, the development of tracking and digital health business and Internet healthcare business using technologies such as cloud computing and big data.
Show More
News
2.0
01-14aastocksShort Selling Activity Reaches $18B, Accounting for 13.1% of Eligible Securities Turnover by Midday
Short Selling Turnover: The short selling turnover in the Hong Kong market reached $18 billion at midday, accounting for 13.1% of the eligible securities turnover, a decrease from 15.7% on the previous trading day.
Top Short Selling Stocks: The top five stocks with the highest short selling amounts include BABA-W, TENCENT, MEITUAN-W, XIAOMI-W, and ALI HEALTH, with short selling ratios ranging from 9.2% to 23.6%.
BABA-W Performance: BABA-W (09988.HK) saw a short selling turnover of $1.95 billion, with a short selling ratio of 9.2%, reflecting a price increase of 5.5%.
MEITUAN-W and XIAOMI-W Trends: MEITUAN-W (03690.HK) and XIAOMI-W (01810.HK) had significant short selling ratios of 22.0% and 23.6%, respectively, indicating bearish sentiment despite their recent price movements.
4.5
01-14aastocksHSI Rises 244 Points at Noon; BABA-W and KUAISHOU-W Jump Over 5%; ALI HEALTH Soars 16%
Market Performance: The HSI rose 244 points (0.9%) to 27,092, with significant gains in tech stocks like HSTECH, which increased by 1.5% to 5,959, and a total market turnover of HKD162.674 billion at midday.
Notable Stock Movements: BABA-W surged 5.3% to HKD168.3, while ALI HEALTH skyrocketed 16% after launching a new drug. KUAISHOU-W and Q TECH also saw substantial increases of 5.5% and 13.5%, respectively.
Short Selling Trends: Various stocks experienced significant short selling, with BABA-W and ALI HEALTH having ratios of 9.235% and 22.547%, respectively, indicating investor caution despite their price increases.
Economic Indicators: China's PPI YoY for December was reported at -1.9%, slightly better than expected, while the inflation rate for the same month was 0.2%, showing a rise from the previous -0.1%.
2.0
01-14aastocksBABA-W's Qianwen Surpasses 100M MAUs; Significant Product Update Expected Tomorrow: Report
BABA-W Stock Performance: BABA-W (09988.HK) saw a 5.3% increase, closing at HKD168.3 with a turnover of HKD21.106 billion, while short selling reached $1.95 billion with a ratio of 9.235%.
Qianwen App Growth: The Qianwen app, launched two months ago, surpassed 100 million monthly active users, particularly gaining traction among students and white-collar workers, with a significant product update expected soon.
ALI HEALTH Surge: ALI HEALTH (00241.HK) experienced a notable 15.9% rise, closing at HKD7.58, with a turnover of HKD3.117 billion and short selling amounting to $702.77 million.
DAMAI ENT Performance: DAMAI ENT (01060.HK) increased by 2.1% by midday, with short selling at $19.97 million and a ratio of 18.752%.
4.5
01-14aastocks<Midday Update> HSI Ends Midday at 27,092, Gaining 244 Points; HSTI Reaches 5,959, Up 89 Points; BABA Surges Over 5%; ALI HEALTH, ZIJIN MINING, CKH HOLDINGS, WANGUO GOLD GP, and WEICHAI POWER Achieve New Highs
Market Performance: The Hang Seng Index (HSI) rose by 244 points (0.9%) to 27,092, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains of 1.5% and 0.9%, respectively.
Active Heavyweights: Notable stock movements included Alibaba (BABA) increasing by 5.3% to $168.3, while Meituan (03690.HK) fell by 3% to $101.8. Tencent (00700.HK) and HKEX (00388.HK) also experienced gains.
Top Gainers: Ali Health (00241.HK) surged by 15.9% to $7.58, reaching a new high, while Haidilao (06862.HK) and Nongfu Spring (09633.HK) rose by 7.4% and 6.1%, respectively.
Significant Movements: Synagistics (02562.HK) saw a remarkable increase of 47.9%, while Dalipal Holding (01921.HK) experienced a significant drop of 12%. Other notable gainers included Q Tech (01478.HK) and AsiaInfo Tech (01675.HK) with increases of 13.5% and 11.1%.
4.5
01-13aastocksHSI Closes Up 239 Points; BABA-W Jumps Over 3%; DONGFENG GROUP Soars Approximately 7%
Market Performance: The HSI rose by 239 points (0.9%) to close at 26,848, with the HSCEI and HSTECH also showing gains, while total market turnover reached HKD315.192 billion.
Technology Sector Highlights: Notable gains were seen in BABA-W (+3.6%) and ALI HEALTH (+2.8%), while some AI stocks like SENSETIME-W and WEIMOB INC experienced declines of 4.9% and 4.5%, respectively.
Chip Stocks Movement: Chip stocks faced losses, with BIREN TECH and ILUVATAR COREX dropping 7.7% and 8.9%, while ASMPT and COWELL saw gains of 3.6% and 8.1%.
Automotive Sector Developments: Supported by a new tariff deal between China and the EU, BYD COMPANY and other car manufacturers like GWMOTOR and XPENG-W saw increases, while XIAOMI-W declined by 2%.
Money Flow
Over the past 66 trading days, overall net money flow is 992.58M, with retail investors contributing 51.96M and major investors adding 927.97M.
Net Buy $ Volume
Net Sell $ Volume
CLSA
CLSA
Outperform
maintain
2025-12-08
Reason
The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.
CLSA
Outperform
Price Target
2025-12-08
maintain
The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.
JPMorgan
JPMorgan
Neutral
maintain
$6.5
2025-12-03
Reason
The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.
JPMorgan
Neutral
Price Target
$6.5
2025-12-03
maintain
The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.
Goldman Sachs
Goldman Sachs
Neutral
maintain
2025-12-02
Reason
Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.
Goldman Sachs
Neutral
Price Target
2025-12-02
maintain
Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.
UBS
downgrade
2025-12-02
Reason
The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.
UBS
Price Target
2025-12-02
downgrade
The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.
CICC
CICC
upgrade
2025-11-28
Reason
The analyst rating for ALI HEALTH (00241.HK) is maintained at "Outperform" due to several key reasons:
1. Strong Financial Performance: The company's 1HFY26 results exceeded expectations, with a revenue increase of 17% year-over-year and a non-GAAP net profit growth of 38.7%. This indicates robust operational performance, particularly in the original prescription drug category.
2. Positive Forecast Adjustments: CICC raised its non-GAAP net profit forecasts for FY2026 and FY2027 by 16%, reflecting confidence in the company's ongoing profitability and growth potential.
3. Strategic Partnerships: The anticipated strengthening of strategic partnerships with upstream enterprises is expected to enhance contributions from areas beyond product sales, indicating a diversified growth strategy.
4. Sector Valuation Uplift: The recent increase in sector valuations has led to a 30% increase in the target price to $7.1, further supporting the positive outlook on the stock.
These factors collectively contribute to the analyst's favorable rating and outlook for ALI HEALTH.
CICC
Price Target
2025-11-28
upgrade
The analyst rating for ALI HEALTH (00241.HK) is maintained at "Outperform" due to several key reasons:
1. Strong Financial Performance: The company's 1HFY26 results exceeded expectations, with a revenue increase of 17% year-over-year and a non-GAAP net profit growth of 38.7%. This indicates robust operational performance, particularly in the original prescription drug category.
2. Positive Forecast Adjustments: CICC raised its non-GAAP net profit forecasts for FY2026 and FY2027 by 16%, reflecting confidence in the company's ongoing profitability and growth potential.
3. Strategic Partnerships: The anticipated strengthening of strategic partnerships with upstream enterprises is expected to enhance contributions from areas beyond product sales, indicating a diversified growth strategy.
4. Sector Valuation Uplift: The recent increase in sector valuations has led to a 30% increase in the target price to $7.1, further supporting the positive outlook on the stock.
These factors collectively contribute to the analyst's favorable rating and outlook for ALI HEALTH.
CLSA
Outperform
maintain
$6.5
2025-11-28
Reason
The analyst rating for ALI HEALTH was set to "Outperform" with a target price of HKD 6.5 due to several factors highlighted in the report. The company's 1HFY26 results slightly exceeded expectations, with both revenue and profit showing advancement driven by strong first-party sales, despite a miss in third-party platform performance. The adjusted net profit increased by 39% year-over-year, and the gross margin of 8.1% surpassed the broker's estimate of 7.7%. Additionally, ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15% and profit growth of 20-30%, indicating confidence in future performance. The broker also anticipates sustained strong growth in sales of originator drugs, although there may be uncertainties in healthcare device sales as the effects of a trade-in program diminish.
CLSA
Outperform
Price Target
$6.5
2025-11-28
maintain
The analyst rating for ALI HEALTH was set to "Outperform" with a target price of HKD 6.5 due to several factors highlighted in the report. The company's 1HFY26 results slightly exceeded expectations, with both revenue and profit showing advancement driven by strong first-party sales, despite a miss in third-party platform performance. The adjusted net profit increased by 39% year-over-year, and the gross margin of 8.1% surpassed the broker's estimate of 7.7%. Additionally, ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15% and profit growth of 20-30%, indicating confidence in future performance. The broker also anticipates sustained strong growth in sales of originator drugs, although there may be uncertainties in healthcare device sales as the effects of a trade-in program diminish.
Citi
Buy
maintain
$8.5
2025-11-27
Reason
The analyst rating for ALI HEALTH (00241.HK) is a "Buy / High Risk" based on several positive financial indicators. The company's interim revenue rose by 17% year-over-year, and its net profit of RMB1.266 billion exceeded expectations. Additionally, ALI HEALTH's adjusted net profit grew by 38.7% year-over-year, and its gross profit margin improved. The company also raised its full-year revenue growth guidance to 10-15% and its adjusted net profit growth guidance to 20-30%. Citi believes that the strong adjusted net profit growth will lead the market to focus on potential further increases in the company's results guidance. The target price set by Citi is HKD8.5.
Citi
Buy
Price Target
$8.5
2025-11-27
maintain
The analyst rating for ALI HEALTH (00241.HK) is a "Buy / High Risk" based on several positive financial indicators. The company's interim revenue rose by 17% year-over-year, and its net profit of RMB1.266 billion exceeded expectations. Additionally, ALI HEALTH's adjusted net profit grew by 38.7% year-over-year, and its gross profit margin improved. The company also raised its full-year revenue growth guidance to 10-15% and its adjusted net profit growth guidance to 20-30%. Citi believes that the strong adjusted net profit growth will lead the market to focus on potential further increases in the company's results guidance. The target price set by Citi is HKD8.5.
BofA Securities
BofA Securities
upgrade
2025-10-15
Reason
The analyst rating for ALI HEALTH (00241.HK) was upgraded to a Buy due to several key factors. BofA Securities predicted that the company will exceed consensus expectations for its results in the current fiscal year ending March 2026. They raised their revenue growth forecast by 4 percentage points to 14% and adjusted the net profit growth forecast by 10 percentage points to 30%. Additionally, the broker increased the adjusted net profit forecast for both the current and next fiscal year by 8% and raised the expected free cash flow compound annual growth rate (CAGR) from 42% to 45%.
The report highlighted robust sales during the "618" shopping event, increased investment by parent company Alibaba (BABA-W) in quick commerce, which boosted traffic on Alibaba Health's platforms, and benefits from higher advertising spending by merchants. These factors contributed to the positive outlook and the increase in the target price from HK$5.5 to HK$6.56.
BofA Securities
Price Target
2025-10-15
upgrade
The analyst rating for ALI HEALTH (00241.HK) was upgraded to a Buy due to several key factors. BofA Securities predicted that the company will exceed consensus expectations for its results in the current fiscal year ending March 2026. They raised their revenue growth forecast by 4 percentage points to 14% and adjusted the net profit growth forecast by 10 percentage points to 30%. Additionally, the broker increased the adjusted net profit forecast for both the current and next fiscal year by 8% and raised the expected free cash flow compound annual growth rate (CAGR) from 42% to 45%.
The report highlighted robust sales during the "618" shopping event, increased investment by parent company Alibaba (BABA-W) in quick commerce, which boosted traffic on Alibaba Health's platforms, and benefits from higher advertising spending by merchants. These factors contributed to the positive outlook and the increase in the target price from HK$5.5 to HK$6.56.
Macquarie
Underperform
to
Outperform
upgrade
2025-08-19
Reason
The analyst rating upgrade from Macquarie for ALI HEALTH (00241.HK) is based on several key factors:
1. Enhanced Profitability: Macquarie has raised its FY26-27 adjusted net profit forecasts for ALI HEALTH by 6% and 20%, respectively, indicating an expectation of improved financial performance due to market consolidation.
2. Structural Improvement in Online Healthcare: The report highlights that the online healthcare industry has seen structural improvements, with a shift in market share from offline to online channels, which is beneficial for ALI HEALTH.
3. Traffic Synergy from Alibaba: The integration of the 88VIP program by ALI HEALTH's parent company, Alibaba, is expected to provide additional traffic synergy benefits, further enhancing ALI HEALTH's market position.
These factors collectively led to the upgrade of the rating from Underperform to Outperform and an increase in the target price from HKD3.4 to HKD6.78.
Macquarie
Underperform
to
Outperform
Price Target
2025-08-19
upgrade
The analyst rating upgrade from Macquarie for ALI HEALTH (00241.HK) is based on several key factors:
1. Enhanced Profitability: Macquarie has raised its FY26-27 adjusted net profit forecasts for ALI HEALTH by 6% and 20%, respectively, indicating an expectation of improved financial performance due to market consolidation.
2. Structural Improvement in Online Healthcare: The report highlights that the online healthcare industry has seen structural improvements, with a shift in market share from offline to online channels, which is beneficial for ALI HEALTH.
3. Traffic Synergy from Alibaba: The integration of the 88VIP program by ALI HEALTH's parent company, Alibaba, is expected to provide additional traffic synergy benefits, further enhancing ALI HEALTH's market position.
These factors collectively led to the upgrade of the rating from Underperform to Outperform and an increase in the target price from HKD3.4 to HKD6.78.
Valuation Metrics
Forward PE
N/A
5Y Average PE
88.04
Current PE
29.77
Overvalued PE
409.67
Undervalued PE
-233.60
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-165.28
Current EV/EBITDA
25.11
Overvalued EV/EBITDA
921.92
Undervalued EV/EBITDA
-1252.48
Forward PS
5Y Average PS
3.22
Current PS
2.03
Overvalued PS
6.12
Undervalued PS
0.32
Financials
Al Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
No data
Short Selling
People Also Watch